MHRA programme to tackle evidence gaps on women’s health

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a women’s health programme to address gaps in evidence on the risks and benefits of medicines and medical devices for women.
The initiative aims to improve understanding of how treatments affect women differently and support the development of healthcare technologies that better meet their needs.
An analysis of 4,616 UK clinical trial applications submitted between 2019 and 2023 found that pregnant women were represented in just 1.1 per cent of trials and breastfeeding women in 0.6 per cent.
MHRA announced the programme on 16 November 2026 as part of efforts to address inequalities in medical research.
Lawrence Tallon, chief executive of the MHRA, said: “Closing the gaps in our understanding of how the risks and benefits of medicines and medical devices differ for women is both a challenge and a huge opportunity.
“Better evidence can help us understand where important differences exist, support researchers and innovators and create opportunities for healthcare that is better tailored to women’s needs.”
Although women account for 51 per cent of the population, they have historically been underrepresented in clinical studies.
Evidence gaps remain particularly significant during pregnancy and across reproductive health, as well as for conditions that affect women differently or disproportionately.
The programme will bring together patients, researchers, healthcare professionals and industry representatives to strengthen evidence on how medicines and medical devices affect women.
Factors including biology, age, pregnancy and existing health conditions can influence treatment responses.
The MHRA wants to improve understanding of these differences while maintaining regulatory standards for safety, quality and effectiveness.
Women’s health minister Baroness Gillian Merron said: “For too long, women’s health has been overlooked.
“Women make up more than half of our population, yet they have been underrepresented in the research that shapes the medicines and devices they rely on.
“That is not good enough, and we are determined to change it.”
Merron said the programme would complement the government’s renewed Women’s Health Strategy.
The agency also plans to work with researchers and developers earlier in the development of new healthcare technologies.
According to the MHRA, the UK’s femtech sector generates nearly £300m in annual turnover, with companies developing products for reproductive health, long-term conditions and healthy ageing.
The agency hopes that stronger evidence will help developers bring promising products to patients sooner.
Another focus is improving representation in clinical research.
The MHRA and Health Research Authority have developed joint guidance on Inclusion and Diversity Plans to help researchers ensure study participants better reflect the people likely to use new treatments.
Naho Yamazaki, deputy director of policy and partnerships at the Health Research Authority, said: “We welcome the MHRA’s Women’s Health Programme and its ambition to strengthen the evidence base for women’s health.
“Ensuring that people who are under-represented in research are considered and included in clinical trials is essential if research is to generate evidence that is relevant to the populations who will ultimately use new medicines and treatments.”
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.









